The immunoglobulin receptor GPVI (glycoprotein VI) is selectively expressed on
megakaryocytes and platelets and is currently recognized as a receptor for not only collagen …

It has previously been shown in several animal experiments that platelet GPVI (glycoprotein
VI) contributes to thrombosis, particularly in ischemic stroke. Moreover, GPVI levels are …

Platelet glycoprotein VI (GPVI) is attracting interest as a potential target for the development
of new antiplatelet molecules with a low bleeding risk. GPVI binding to vascular collagen …

Platelets play a central role in arrest of bleeding. The ability of platelets to engage with
extracellular matrix proteins of the subendothelium has long been recognised as a pivotal …

Impairment of vascular integrity is a hallmark of inflammatory diseases. We recently reported
that single immune-responsive platelets migrate and reposition themselves to sites of …

Abstract Background The glycoprotein VI (GPVI) signaling pathway was previously reported
to direct procoagulant platelet activity through collagen binding. However, the impact of …

Genetic variants within the fibrinogen Aα chain encoding the αC-region commonly result in
hypodysfibrinogenemia in patients. However, the (patho) physiological consequences and …

Collagen has been proposed to bind to a unique epitope in dimeric glycoprotein VI (GPVI)
and the number of GPVI dimers has been reported to increase upon platelet activation …

Acute ischemic stroke (AIS) is the most common type of stroke and requires immediate
reperfusion. Current acute reperfusion therapies comprise the administration of intravenous …

Antiplatelet therapy aims to reduce the risk of thrombotic events while maintaining
hemostasis. A promising current approach is the inhibition of platelet glycoprotein GPVI …